Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Dimethyl fumarate (BG-12, Tecfidera) - NICE says yes in draft final guidance
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells.
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Multiple Sclerosis.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
NOVANTRONE. mitoXANTRONE for injection concentrate
CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation.
The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Ampyra (dalfampridine)
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Identical lesion morphology in primary progressive and relapsing-remitting MS -an ultrahigh field MRI study.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.

Pages